EICHORCondition: Crohn's Disease · Sponsor: Reistone Biopharma Company Limited
The proposed study is a randomized, double-blind, placebo-controlled, multi-center Phase II study to investigate the safety and efficacy of SHR0302 in patients with moderate to severe active Crohn's Disease. The study aims to evaluate the optimal dose of SHR0302 and time needed in inducing clinical remission in active CD. This is an 12+12 weeks study, in which participants who complete the first 12 weeks treatment phase, will have the option to enter a blinded active arms 12-week extension phase. Early withdrawn subjects during the first treatment phase cannot enter the extension phase. The total duration of the study participation, including extension and follow-up, will be approximately 26 weeks. With the wealth of scientific evidence on JAK/STAT involvement in IBD, the data from similar class of new drugs and the current data on SHR0302 (JAK1 inhibitor), support the rationale to proceed with phase II studies to evaluate the efficacy and safety of SHR0302 in patients with moderate to severe active CD.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Male and Female subject at ≥18 and ≤ 75 years of age at randomization. * Subjects with a documented three-month history of diagnosed ileal, colonic, or ileocolonic Crohn's Disease at the time of randomization. * Currently having Crohn's Disease with Crohn's Disease Activity Index (CDAI) score ≥ 220 to ≤450. Exclusion Criteria: * Diagnosis of indeterminate colitis, or clinical findings suggestive of Ulcerative Colitis. * Subject with CD with stoma, gastric or ileoanal pouch, proto-colectomy or total colectomy, symptomatic stenosis or stricture, history of bowel perforation, suspected abscess; actively draining fistula. * Treatment naïve subjects diagnosed with Crohn's disease, (without previous exposure to treatment).
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| West Central Gastroenterology d/b/a Gastro Florida | Clearwater, Florida, United States | — |
| Wellness Clinical Research, LLLC-Central Florida | Lake Wales, Florida, United States | — |
| West Central Gastroenterology d/b/a Gastro Florida | Tampa, Florida, United States | — |
| NECCR Primacare Research, LLC | Fall River, Massachusetts, United States | — |
| Wilmington Health | Wilmington, North Carolina, United States | — |
| Digestive Disease Specialists, Inc. | Oklahoma City, Oklahoma, United States | — |
| The First Affiliated Hospital of Bengbu Medical College | Bengbu, Anhui, China | — |
| Yijishan Hospital of Wannan Medical College | Yingshan, Anhul, China | — |
| Peking University Third Hospital | Beijing, Beijing Municipality, China | — |
| Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | — |
| The First Affiliated Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | — |
| The First Affiliated Hospital of Nanchang University | Guangzhou, Guangzhou, China | — |
+ 70 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03677648